Author

William Sandborn 1

1 Robarts Clinical Trials Inc.,London,Canada

AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS

Ahmed Almradi, Christopher Ma, Geert R. D'Haens, William Sandborn, Claire Parker, Leonardo Guizzetti, Paula Borralho Nunes, Geert De Hertogh, Roger M. Feakins, Reena Khanna, Gregory Y. Lauwers, Aart Mookhoek, Reet Pai, Laurent Peyrin-Biroulet, Robert Riddell, Christophe Rosty, David F. Schaeffer, Mark Valasek, Brian G. Fe

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romańczyk, Hao Chai, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Satish Keshav, Silvio Danese

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Kartik Raghupathi, Robin Osterhout, Brian Feagan, William J. Sandborn, Courtney Van Biene, Allan Olson, Richard Aranda, Barrett G. Levesque, Silvio Danese

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, James D Lewis, Julian Panés, Edward V. Loftus, Jr, Geert R. D'Haens, ZHUQING YU, Bidan Huang, Ana P. Lacerda, Aileen L Pangan, Brian G. Feagan

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN’S DISEASE

William Sandborn

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

CHARACTERIZATION OF MUCOSAL HEALING WITH ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE FROM EXTEND

Walter Reinisch, Jean-Frederic Colombel, Geert R. D'Haens, William Sandborn, Paul Rutgeerts, Joel Petersson, Samantha Eichner, Annalisa Iezzi, Roopal B Thakkar

CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel, Paul Rutgeerts, William Sandborn, Douglas C. Wolf, Walter Reinisch, Gert Van Assche, Samantha Eichner, Joel Petersson, Anne M. Robinson, Roopal B Thakkar

Item 11 - 20 / 206
1
2
3 4 5 6 7
...
20 21